Franklin M E, Gonzalez J J, Michaelson R P, Glass J L, Chock D A
Texas Endosurgery Institute, 4242 E Southcross, Suite 1, San Antonio, TX 78222, USA.
Hernia. 2002 Dec;6(4):171-4. doi: 10.1007/s10029-002-0078-9. Epub 2002 Oct 19.
Surgisis (Cook Surgical, Bloomington, Ind., USA) is a new four-ply bioactive, prosthetic mesh for hernia repair derived from porcine small-intestinal submucosa. It is a naturally occurring extracellular matrix which is easily absorbed, supports early and abundant new vessel growth, and serves as a template for the constructive remodeling of many tissues. As such, we believe that Surgisis mesh is ideal for use in contaminated or potentially contaminated fields in which ventral, incisional, or inguinal hernia repairs are required. From November 2000 through May 2002, 25 patients (11 male, 14 female) underwent placement of Surgisis mesh for a variety of different hernia repairs. A total of 25 hernia repairs were performed in our patient population. Fourteen procedures (56%) were performed in a potentially contaminated setting (i.e. with incarcerated/strangulated bowel within the hernia or coincident with a laparoscopic cholecystectomy/colectomy). Eleven repairs (44%) were performed in a grossly contaminated field, including one in which an infected polypropylene mesh from a previous inguinal hernia repair was replaced with Surgisis and one in which necrotic bowel was discovered within the hernial sac. Median follow-up was 15 months with a range of 1-20 months. Of the 25 total repairs, there was one wound infection complicated by enterocutaneous fistula in a patient originally operated on for ischemic bowel. The fistula was in a location independent of the Surgisis mesh. There were no mesh-related complications or recurrent hernias in our early postoperative follow-up period. Surgisis mesh appears to be a promising new prosthetic material for hernia repair, especially in contaminated or potentially contaminated fields. Obviously, long-term follow-up is still required.
Surgisis（美国印第安纳州布卢明顿市库克外科公司生产）是一种新型的四层生物活性人工合成补片，用于疝修补，取材于猪小肠黏膜下层。它是一种天然存在的细胞外基质，易于吸收，能促进早期大量新血管生长，并作为许多组织进行建设性重塑的模板。因此，我们认为Surgisis补片非常适合用于需要进行腹侧、切口或腹股沟疝修补的污染或潜在污染区域。从2000年11月至2002年5月，25例患者（11例男性，14例女性）接受了Surgisis补片植入术，用于各种不同的疝修补。我们的患者群体共进行了25例疝修补手术。14例手术（56%）是在潜在污染环境下进行的（即疝内伴有嵌顿/绞窄性肠管或与腹腔镜胆囊切除术/结肠切除术同时进行）。11例修补手术（44%）是在严重污染区域进行的，其中1例是将先前腹股沟疝修补术中感染的聚丙烯补片更换为Surgisis补片，另1例是在疝囊内发现坏死肠管。中位随访时间为15个月，范围为1至20个月。在总共25例修补手术中，1例最初因缺血性肠管接受手术的患者发生了伤口感染，并伴有肠皮肤瘘。瘘管位置与Surgisis补片无关。在术后早期随访期间，未出现与补片相关的并发症或复发性疝。Surgisis补片似乎是一种有前景的新型疝修补人工合成材料，尤其适用于污染或潜在污染区域。显然，仍需要进行长期随访。
